Medicamen Biotec

Why is Medicamen Biotech Ltd falling/rising?

As of 04-Aug, Medicamen Biotech Ltd's stock price is rising to 249.30, up 4.55%, driven by strong relative performance and increased investor participation. Despite a year-to-date decline of 31.33%, recent trends suggest a short-term recovery.

As of 04-Aug, Medicamen Biotech Ltd's stock price is rising, currently at 249.30, reflecting an increase of 10.85 or 4.55%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 4.06% today, indicating strong relative performance. Additionally, it has been gaining for the last two days, with a total return of 5.11% during this period. The stock opened with a gain of 2.35% today and reached an intraday high of Rs 258, which is an increase of 8.2%. <BR><BR>Moreover, there has been a notable rise in investor participation, with delivery volume on 03 Aug increasing by 133.64% compared to the 5-day average. This suggests heightened interest and confidence among investors. Despite the stock's longer-term performance showing declines over various periods, including a year-to-date drop of 31.33%, the recent positive trends indicate a short-term recovery phase. Overall, these factors contribute to the current rise in Medicamen Biotech Ltd's stock price.

Which are the latest news on Medicamen Biotec?

Should I buy, sell or hold Medicamen Biotech Ltd?

How big is Medicamen Biotec?

As of 10th June, Medicamen Biotech Ltd has a market capitalization of 325.00 Cr, with recent net sales of 197.77 Cr and a net profit of 10.87 Cr. The company's shareholder's funds are 213.05 Cr, and total assets amount to 294.32 Cr.

As of 10th June, Medicamen Biotech Ltd has a market capitalization of 325.00 Cr, which categorizes it as a Micro Cap company.<BR><BR>In the latest four quarters, Medicamen Biotech reported Net Sales of 197.77 Cr and a Net Profit of 10.87 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 213.05 Cr and Total Assets of 294.32 Cr.

Who are in the management team of Medicamen Biotec?

The management team of Medicamen Biotec includes Sanjay Bansal (Director), Rahul Bishnoi (Chairman), Ashwani Kumar Sharma (Director), and several independent directors, among others, who oversee the company's strategic direction and regulatory compliance.

The management team of Medicamen Biotec includes the following individuals:<BR><BR>1. Sanjay Bansal - Director<BR>2. Rahul Bishnoi - Chairman (Non-Executive)<BR>3. Ashwani Kumar Sharma - Director<BR>4. Harish Pande - Independent Director<BR>5. S K Singh - Director<BR>6. Arun Kumar - Independent Director<BR>7. Parul Choudhary - Company Secretary & Compliance Officer<BR>8. Sumita Dwivedi - Independent Director<BR>9. Vimal Kumar Shrawat - Director<BR>10. Sangeeta Bishnoi - Independent Director<BR>11. Ravi Kumar Bansal - Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and ensuring compliance with regulatory requirements.

Who are the peers of the Medicamen Biotec?

Medicamen Biotec's peers include Albert David, Valiant Laborato, Medico Remedies, Transchem, Trident Lifeline, Zenotech Lab., Astonea Labs, Ambalal Sarabhai, and Infinium Pharma. Key insights show varying management risks, growth rates, and capital structures, with Medicamen Biotec experiencing a 1-year return of -46.53%.

Peers: The peers of Medicamen Biotec are Albert David, Valiant Laborato, Medico Remedies, Transchem, Trident Lifeline, Zenotech Lab., Astonea Labs, Ambalal Sarabhai, and Infinium Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Albert David and Zenotech Lab., while Average management risk is found at Medicamen Biotec, Transchem, Trident Lifeline, Astonea Labs, and the rest. Good growth is seen at Valiant Laborato, Medico Remedies, Trident Lifeline, and Zenotech Lab., while Below Average growth is noted at Medicamen Biotec, Albert David, Transchem, and the rest. Excellent capital structure is present at Albert David, Medicamen Biotec, and Infinium Pharma, while Below Average capital structure is found at Valiant Laborato, Transchem, Astonea Labs, and the rest.<BR><BR>Return Snapshot: Transchem has the highest 1-year return at 605.82%, while Valiant Laborato has the lowest at -40.70%. Medicamen Biotec's 1-year return of -46.53% is lower than both. Additionally, peers such as Medico Remedies, Trident Lifeline, Zenotech Lab., Ambalal Sarabhai, and Infinium Pharma have negative six-month returns.

What does Medicamen Biotec do?

Medicamen Biotech Ltd is a research-driven pharmaceutical company focused on developing, manufacturing, and marketing finished dosage formulations. As of March 2026, it reported net sales of 61 Cr and a net profit of 4 Cr, with a market cap of INR 325 Cr.

Overview: <BR>Medicamen Biotech Ltd is a research-led pharmaceutical company engaged in the development, manufacturing, and marketing of finished dosage formulations, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>History: <BR>Medicamen Biotech Ltd was incorporated in an unspecified year and has maintained its status as a diversified enterprise. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 61 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 4 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 325 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 29.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.42% <BR>Debt-Equity: 0.06 <BR>Return on Equity: 3.94% <BR>Price to Book: 1.18 <BR><BR>Contact Details: <BR>Address: 1506 Chiranjiv Tower 43, Nehru Place New Delhi New Delhi : 110019 <BR>Phone: 91-11-47589500 <BR>Email: cs@medicamen.com <BR>Website: http://www.medicamen.com

Are Medicamen Biotech Ltd latest results good or bad?

Medicamen Biotech Ltd's latest Q4 FY26 results show strong revenue and profit growth, but concerns about declining operating margins and reliance on non-operating income suggest caution for investors regarding long-term sustainability. The stock has also underperformed compared to the broader pharmaceutical sector.

Medicamen Biotech Ltd's latest results for Q4 FY26 present a mixed picture. On one hand, the company achieved a record revenue of ₹60.65 crores, marking a significant growth of 29.29% quarter-on-quarter and an impressive 104.83% year-on-year. Additionally, the net profit rose to ₹3.86 crores, reflecting a strong sequential increase of 76.26% and a year-on-year growth of 59.50%. <BR><BR>However, there are notable concerns beneath these positive figures. The operating margin, excluding other income, has declined to 8.97% from 9.34% in the previous quarter, indicating ongoing margin compression. This trend raises questions about the sustainability of the company's profitability. Furthermore, the reliance on non-operating income, which constituted a significant portion of profit before tax, casts doubt on the quality of earnings.<BR><BR>Overall, while the quarterly performance shows tactical improvement, the underlying issues of margin compression, weak return ratios, and a high valuation relative to peers suggest caution for investors. The stock has also underperformed significantly compared to the broader pharmaceutical sector, which adds to the concerns about its long-term viability.

When is the next results date for Medicamen Biotech Ltd?

The next results date for Medicamen Biotech Ltd is 27 May 2026.

The next results date for Medicamen Biotech Ltd is scheduled for 27 May 2026.

Is Medicamen Biotec overvalued or undervalued?

As of November 14, 2025, Medicamen Biotec is considered expensive and overvalued with a PE ratio of 58.40 and an EV to EBITDA of 38.85, despite a slight improvement in valuation grade, as evidenced by its poor stock performance of -19.84% year-to-date compared to the Sensex's 8.22% gain.

As of 14 November 2025, Medicamen Biotec's valuation grade has moved from very expensive to expensive, indicating a slight improvement in perceived value. However, the company is still considered overvalued. The key ratios highlight this situation, with a PE ratio of 58.40, an EV to EBITDA of 38.85, and a PEG ratio of 2.88, all of which are significantly higher than industry norms.<BR><BR>In comparison to its peers, Medicamen Biotec's PE ratio stands out against Sun Pharma's 36.49 and Torrent Pharma's 60.06, while its EV to EBITDA ratio is higher than both Sun Pharma and Cipla, which has an attractive EV to EBITDA of 16.08. The company's recent stock performance has been lackluster, with a year-to-date return of -19.84%, contrasting sharply with the Sensex's gain of 8.22% during the same period, further reinforcing the notion that Medicamen Biotec is overvalued in the current market context.

How has been the historical performance of Medicamen Biotec?

Medicamen Biotec's historical performance shows a decline in net sales from 179.31 Cr in March 2024 to 162.55 Cr in March 2025, with a drop in operating profit and profit after tax, while total assets and liabilities slightly increased. Cash flow from operating activities remained negative at -6.00 Cr for both years.

Answer:<BR>The historical performance of Medicamen Biotec shows fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Medicamen Biotec's net sales peaked at 179.31 Cr in March 2024 but declined to 162.55 Cr by March 2025. The total operating income followed a similar trend, decreasing from 179.31 Cr in March 2024 to 162.55 Cr in March 2025. The raw material costs also saw a decrease from 104.70 Cr in March 2024 to 90.65 Cr in March 2025, while employee costs increased slightly from 30.07 Cr to 31.87 Cr in the same period. Operating profit (PBDIT) fell from 24.57 Cr in March 2024 to 20.11 Cr in March 2025, reflecting a decline in operating profit margin from 12.4% to 8.53%. Profit before tax decreased from 13.08 Cr to 9.88 Cr, leading to a profit after tax of 6.56 Cr in March 2025, down from 9.49 Cr the previous year. The earnings per share (EPS) also dropped from 8.64 to 5.24. On the balance sheet, total assets increased from 292.04 Cr in March 2024 to 294.32 Cr in March 2025, while total liabilities rose slightly from 292.04 Cr to 294.32 Cr. Cash flow from operating activities remained negative at -6.00 Cr for both March 2024 and March 2025, indicating ongoing challenges in generating cash from operations.

What is the technical trend for Medicamen Biotec?

As of June 2, 2025, Medicamen Biotec's technical trend has shifted to a strong bearish outlook, supported by bearish signals from MACD, Bollinger Bands, and moving averages across multiple time frames.

As of 2 June 2025, the technical trend for Medicamen Biotec has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from multiple time frames. The MACD is bearish on both the weekly and monthly charts, and Bollinger Bands also reflect a bearish trend in both time frames. Daily moving averages confirm a bearish outlook. While the KST shows a mildly bullish signal on the monthly, it is overshadowed by the overall bearish sentiment from other indicators. The Dow Theory indicates a mildly bearish trend on the weekly, and the OBV is also mildly bearish across both weekly and monthly periods. Overall, the technical indicators strongly support a bearish stance.

Who are the top shareholders of the Medicamen Biotec?

The top shareholders of Medicamen Biotec are Shivalik Rasayan Limited with 43.16%, followed by Pharmadanica A/s at 10.54%, and individual investors holding 31.58%. There are no pledged promoter holdings or mutual funds invested in the company, and foreign institutional investors hold a combined 0.22%.

The top shareholders of Medicamen Biotec include Shivalik Rasayan Limited, which holds the largest stake at 43.16%. The highest public shareholder is Pharmadanica A/s, owning 10.54%. Additionally, individual investors collectively hold 31.58% of the shares. There are also 4 foreign institutional investors (FIIs) that hold a combined 0.22% of the company. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

Has Medicamen Biotec declared dividend?

Yes, Medicamen Biotech Ltd has declared a 10% dividend, amounting to ₹1 per share, with an ex-date of September 19, 2024. Despite the dividend, the company has experienced significant declines in price returns over shorter periods, with a total return of 62.16% over the last 5 years.

Medicamen Biotech Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 19 Sep 24<BR><BR>Dividend Yield: 0.22%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -28.9%, the dividend return was 0%, resulting in a total return of -28.9%.<BR><BR>Over the past year, the price return was -11.58%, with a dividend return of 0.21%, leading to a total return of -11.37%.<BR><BR>In the 2-year period, the price return was -38.7%, the dividend return was 0.29%, culminating in a total return of -38.41%.<BR><BR>For the 3-year period, the price return stood at -38.25%, the dividend return was 0.51%, which resulted in a total return of -37.74%.<BR><BR>In the 4-year period, the price return was -21.11%, with a dividend return of 0.73%, leading to a total return of -20.38%.<BR><BR>Over the last 5 years, the price return was 60.54%, the dividend return was 1.62%, resulting in a total return of 62.16%.<BR><BR>Overall, while Medicamen Biotech Ltd has declared a dividend, the total returns over various periods show significant declines in price returns, particularly in the shorter terms, with the most positive performance observed over the 5-year period.